Loading...
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial
Tolaney, SM Wardley, Andrew M Zambelli, S Hilton, JF Troso-Sandoval, TA Ricci, F Im, SA Kim, SB Johnston, SR Chan, A
Tolaney, SM
Wardley, Andrew M
Zambelli, S
Hilton, JF
Troso-Sandoval, TA
Ricci, F
Im, SA
Kim, SB
Johnston, SR
Chan, A
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2020
Publisher
Collections
Keywords
Type
Article
Citation
Tolaney SM, Wardley AM, Zambelli S, Hilton JF, Troso-Sandoval TA, Ricci F, et al. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial. Lancet Oncol. 2020;21(6):763-75.